

# PHARMACEUTICAL SERVICES (SCOTLAND) ADDITIONAL SERVICES

## **Forth Valley Community Pharmacy Naloxone Service**

#### 1. Service aims

- 1.1. To support the National Naloxone Programme to increase awareness and the availability of training and supply across NHS Forth Valley.
- 1.2. To provide training and supply naloxone via patient group direction, to clients at risk of opiate overdose who have engaged in an approved training programme.
- 1.3. To help clients who use the service to access other health, voluntary and social care services where appropriate to facilitate behaviour change in their journey towards recovery.

#### 2. Service outline and standards

#### 2.1 Service Provision

- 2.1.1 The Community Pharmacy Naloxone Service will be provided by community pharmacies engaged in Injecting Equipment Provision (IEP) and any other community pharmacy providing services to patients on opiate replacement therapy.
- 2.1.2 The training element of the service will be provided by the pharmacist or staff member who must have attended the approved naloxone training. This element may be supported by an approved DVD presentation.
- 2.1.3 The naloxone supply element of the service will be provided by the pharmacist who must have attended the approved naloxone training.
- 2.1.4 The pharmacist is responsible for ensuring that the service is user-friendly, non-judgemental, client-centred and confidential service.
- 2.1.5 The pharmacy team will be responsible for developing and maintaining a close working relationship with the local harm reduction service and all Substance Misuse Treatment Services. This should include a process to allow information sharing where required.
- 2.1.6 The premises should provide an acceptable level of confidentiality and safety as agreed on a local basis. This should reflect the needs of the client and other members of the public.



- 2.1.7 The pharmacist will provide support, advice and information to clients who use this service, including signposting or referral to other broader health and social support services. These will include:
  - Harm Reduction Service drop-ins
  - Local substance misuse treatment services
  - Hepatology services for BBV testing and treatment
- 2.1.8 A standard operating procedure should be in place in the pharmacy to cover all aspects of service provision.
- 2.1.9 NHS Forth Valley will provide a local patient group direction within which this service must be operated.
- 2.1.10 The pharmacist will ensure that the pharmacy staff consider and, where appropriate, act on any child protection issues coming to their attention as a result of providing the service.

### 2.2 Assessment, Brief Intervention and Naloxone Supply

- 2.2.1 All clients attending the service for the first time should be welcomed and asked some basic information about the naloxone programme to ensure their needs are met. The client must be given or have previously received training on:
  - risks and signs of opiate overdose
  - basic life support
  - naloxone administration.

Where possible/available the client's details should be confirmed by searching the NEO naloxone module.

The discussion should take place in a private area to ensure confidentiality and should include the provision of both verbal and written information about the naloxone programme.

- 2.2.2 Verification of the client's knowledge and understanding of all aspects of the programme should be confirmed by utilising the checklist (appendix 1).
- 2.2.3 Only in exceptional circumstances should a supply of naloxone be refused and professional judgement should be used.
- 2.2.4 For those clients who have been trained onsite and/or provide evidence of being trained and when the pharmacist is assured that the client understands:
  - the risks and signs of opiate overdose
  - how to administer basic life support and
  - naloxone administration

the Pharmacist will make a supply of 'take home naloxone' as determined by the patient group direction as part of the Forth Valley Naloxone Programme.



- Supporting education materials will be supplied by Forth Valley Alcohol and Drug Partnership for issue to clients.
- 2.2.5 The pharmacist will be responsible for ordering replacement stock and maintaining adequate stock levels. All purchases must be claimed from NHS Forth Valley by sending a copy of the invoice to the Finance Department.

#### 2.3 Data collection

- 2.3.1 The pharmacist is responsible for ensuring that the minimum data set is collected as agreed locally.
- 2.3.2 Data collection systems should be used in accordance with local protocols. The aim is locally to move towards direct entry on to the web based electronic system. Where direct entry is not feasible then the paper Naloxone Training and Supply Record (appendix 2) should be used with regular batch entry of this data on to the electronic system. Confidentiality and data protection should be maintained.

#### 3 Training

- 3.1 NHS Forth Valley will ensure that relevant training is made available to pharmacy staff involved in Forth Valley Community Pharmacy Naloxone Service. The pharmacist must have attended an approved naloxone training course prior to commencing the service. Updates will be provided as part of the broader IEP training on an annual basis.
- 3.2 All staff should have read the 'Guidelines for services providing injecting equipment. Best practice recommendations for commissioners and IEP services in Scotland' (Scottish Government 2010).
- 3.3 It is essential that pharmacists participate in any local and national training initiatives identified by NHS Forth Valley.
- 3.4 The pharmacist will ensure that they have up-to-date knowledge, are aware of local arrangements and are appropriately trained in the operation of the service.

#### 4. Monitoring and evaluation

4.1 It is a requirement of the service that appropriate records are kept and maintained by the pharmacist to enable verification of service provision and training requirements, and to provide information to NHS Forth Valley for internal and external audit and evaluation purposes.



- 4.2 NHS Forth Valley should ensure effective monitoring and audit of the service.
- 4.3 The pharmacist is responsible for participating in local and national evaluation and facilitating local customer feedback initiatives.

## 5. Payment

- 5.1 A fee will be paid for providing this service. This will include the provision of training and/or a 'take home naloxone' kit with written and verbal advice to clients.
- 5.2 Payment for service provision shall be made following submission of a fully completed claim form or invoice from NEO system on a monthly basis. Information on this form is also used for audit and evaluation purposes and must be completed accurately before any payment is made by NHS Forth Valley.



#### **Background Information – not part of the service specification**

RPSGB Medicines, Ethics and Practice Guide (current edition)

NES Child Protection Distance Learning Resource Pack

National Forum on Drug Related Deaths in Scotland: Annual Report 2010-11 <a href="http://www.scotland.gov.uk/Publications/2011/11/09091958/0">http://www.scotland.gov.uk/Publications/2011/11/09091958/0</a>

Scottish Drugs Forum <a href="http://naloxone.org.uk">http://naloxone.org.uk</a>

#### **Useful references**

Guidelines for Services Providing Injecting Equipment http://www.scotland.gov.uk/Publications/2010/03/29165055/0

National quality standards for drug misuse services http://www.scotland.gov.uk/resource/Doc/149486/0039796.pdf

National Treatment Agency: best practice guidance for commissioners and providers of pharmaceutical services for drug users <a href="http://www.nta.nhs.uk/publications/Prescribing/Pharmaceutical\_services for drug users.pdf">http://www.nta.nhs.uk/publications/Prescribing/Pharmaceutical\_services for drug users.pdf</a>

Website run by independent academics and healthcare professionals aimed at raising the awareness and profile of the use of take-home naloxone as a mechanism for reducing drug-related death, and to provide a forum for discussing innovation, training and practice developments: <a href="http://www.take-homenaloxone.org">http://www.take-homenaloxone.org</a>

Guidelines for the prevention, testing, treatment and management of hepatitis C in Primary care available at <a href="https://www.smmgp.org.uk">www.smmgp.org.uk</a>and <a href="https://www.rcgp.org.uk">www.rcgp.org.uk</a>



# One to One Naloxone Training Checklist

Trainee Details							
Name	DOB	Address (inc. postcode)	GP Name & A	Address			
The person must demonstrate an understanding of the following:							
The most common drugs identified in a drug-related death (heroin,							
methadone, diazepam & alcohol – all CNS depressant drugs) and the physical							
effects these drugs	have (slow, sha	allow, irregular breathing, slo	ow heart rate,				
feeling less alert, und	consciousness,	poor memory, not feeling pa	in, lower body				
temp)							
The main causes of	drug overdose	e (low tolerance, polydrug us	se, using too much,				
using alone, injecting	g drug use, pur	ity levels)					
High risk times (rel	ease from priso	on, leaving rehab or hospital,	recent detox,				
recent relapse, poor physical or mental health, recent life events, cash windfall,							
longer-term user, festive periods, weekends or holidays)							
The signs & sympto	oms of suspect	ed opiate overdose (pinpoin	t pupils, breathing				
problems, skin/lip colour, no response to noise or touch, loss of consciousness)							
The common myths (don't inflict pain, give other drugs e.g. stimulants, put in							
bath/shower, walk person around, leave person on own)							
Knows when to call 999 (when person won't wake with shout/shake, status of							
person and location)							
Knows about the recovery position (person on side, airway open)							
Knows about rescue breathing and CPR (30 compressions, 2 breaths – one							
cycle of BLS)							
Knows when and how to administer naloxone (unconscious but breathing –							
admin when in recovery position then every 2-3mins, unconscious but NOT							
breathing – admin after one cycle of BLS then after every three cycles of BLS.							
Dose – 0.4mls into outer thigh muscle via clothing. Assembly of syringe)							
Knows that naloxon	ne is short acti	<b>ng</b> (the effects of naloxone v	vear off after 20-				
30 mins, possible that overdose may return)							
Knows the importance of staying with the person (do not let the person use any							
other drugs if they g	ain consciousne	ess)					
The above trainee has demonstrated an understanding and awareness of opiate overdose, the use of naloxone, calling 999, the recovery position and basic life support and is eligible to receive a supply of take home naloxon							
canning 777, the recovery position and basic me support and is engine to receive a suppry of take nome natioxon							
Trainer Name							
Pharmacy Name & Address.							



# Naloxone Training & Supply Record

1.	. Pharmacy Service:				Prison release/court date				
2	ADD area of	<sup>p</sup> oliont.	Closles	Ctinlin		Dollsink f	_		
4.	ADP area of	chent:	Clacks	Suriing	g 🔟	Falkirk (	J		
3.	Client Iden	tifier: Gender: Initials (1 <sup>st</sup> letter Date of birth (e.g			etter o	f surname)	:	Not Specified □	
								vice/Prison Worker 🗖	
4.	Client deta	ils: First Na Last na							
		Address (service Town/C	address for w	ŕ					
		Telepho	le						
5.	Client only	GP nam GP add	ne ress					us   Service	
		Is the client in s	tructured tre	atment?	No 🗖	Yes □	Se	rvice:	· <b>··</b>
6.	Training:	Training details							
		Training given o Training given b							
						(	Completed	d (✓) Offered but decline	ed
		Training element	ts				_	-	
		OD awareness Heartstart/CPR							
		Naloxone admin	istration						
adı ab Re	ministration o ove ason given: ient' Signature	offered training if naloxone and at	this point in	time <u>I ha</u>	Date:	cided to d	ecline tra	pport and the appropriate ining elements recorded worker's signature	<u>l</u>



7. Consent options  I consent to the sharing for the purpose of monito in accordance with the Da	ring and evaluat	ing training an						
☐ I consent for my repres	entative			to	hold nalo	xone on my bel	nalf.	
☐ I decline a supply of na	lloxone							
Person giving consent (cli	ent):		Si	gnature:				
Witnessed by (trainer):		Date:		•••••				
NALOXONE SUPPLY I 8. Supply details	DETAILS							
o. Supply uctans	Supply to:	Person at risk		Family/Fr	iends 🗖	Service/Prise	on Worker 🗖	
	Supply Type:		First	Supply [	l Repe	at supply	Not known	
	Supply date Naloxone as: Batch number Expiry date  Spare supply Batch number Expiry date		naloxone prefilled syringe for injection 2mg/2ml kited)					
Supplied	d by:		Si	gnature:				
9. Reason for re-supply	pply		☐ Kit	t confiscate	d			
	☐ Used on other☐ Used on self☐		☐ Kit Expired					
			☐ Kit Lost ☐ Kit Stolen					
☐ Not known			☐ Kit damaged					
DETAILS OF NALOXO	ONE USE (Option	onal)						
11. Outcome:		☐ Resuscita	tion su tion un	successful				
12. Further comments:								